Cytokinetics, Incorporated

NasdaqGS:CYTK Stock Report

Market Cap: US$5.7b

Cytokinetics Management

Management criteria checks 3/4

Cytokinetics' CEO is Robert Blum, appointed in Feb 2006, has a tenure of 18.83 years. total yearly compensation is $8.75M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $13.57M. The average tenure of the management team and the board of directors is 3.7 years and 11.8 years respectively.

Key information

Robert Blum

Chief executive officer

US$8.8m

Total compensation

CEO salary percentage9.0%
CEO tenure18.8yrs
CEO ownership0.2%
Management average tenure3.7yrs
Board average tenure11.8yrs

Recent management updates

Recent updates

A Look At The Intrinsic Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)

Dec 14
A Look At The Intrinsic Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)

Cytokinetics: On The Cusp Of Commercialization

Nov 14

Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities

Aug 13

Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Aug 11
Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes

Jul 24

Cytokinetics Decides To Go It Alone

May 24

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

May 09
Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

Cytokinetics, Incorporated: Buyout Speculation Persists

Apr 01

Cytokinetics: CEO Talks Down Buyout Prospects

Mar 16

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Jan 12

CEO Compensation Analysis

How has Robert Blum's remuneration changed compared to Cytokinetics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$576m

Jun 30 2024n/an/a

-US$545m

Mar 31 2024n/an/a

-US$531m

Dec 31 2023US$9mUS$790k

-US$526m

Sep 30 2023n/an/a

-US$527m

Jun 30 2023n/an/a

-US$540m

Mar 31 2023n/an/a

-US$431m

Dec 31 2022US$9mUS$742k

-US$389m

Sep 30 2022n/an/a

-US$282m

Jun 30 2022n/an/a

-US$216m

Mar 31 2022n/an/a

-US$258m

Dec 31 2021US$6mUS$709k

-US$215m

Sep 30 2021n/an/a

-US$229m

Jun 30 2021n/an/a

-US$156m

Mar 31 2021n/an/a

-US$135m

Dec 31 2020US$5mUS$682k

-US$127m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$140m

Mar 31 2020n/an/a

-US$132m

Dec 31 2019US$3mUS$656k

-US$122m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$110m

Mar 31 2019n/an/a

-US$105m

Dec 31 2018US$3mUS$630k

-US$106m

Sep 30 2018n/an/a

-US$120m

Jun 30 2018n/an/a

-US$131m

Mar 31 2018n/an/a

-US$132m

Dec 31 2017US$3mUS$612k

-US$128m

Compensation vs Market: Robert's total compensation ($USD8.75M) is about average for companies of similar size in the US market ($USD7.98M).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.

CEO

Robert Blum (60 yo)

18.8yrs

Tenure

US$8,751,057

Compensation

Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and served as its Principal Financial Officer until May 08, 2024. Mr. Blum p...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Blum
CEO, President & Director18.8yrsUS$8.75m0.24%
$ 13.6m
Robert Wong
VP, Principal Accounting Officer & Chief Accounting Officer5.6yrsUS$1.04m0.0074%
$ 422.7k
Fady Malik
Executive Vice President of Research & Development12.5yrsUS$4.44m0.051%
$ 2.9m
Andrew Callos
Executive VP & Chief Commercial Officer3.8yrsUS$3.20m0.023%
$ 1.3m
James Spudich
Co-Founder & Member of Scientific Advisory Board27.3yrsUS$21.94kno data
Sung Lee
Executive VPless than a yearno data0.0023%
$ 134.0k
Jeff Lotz
Vice President of Sales & Operations3.3yrsno datano data
Matt Yang
Vice President of Corporate Finance and Financial Planning & Analysis1.1yrsno datano data
Steven Cook
Senior Vice President of Global Supply Chain Operations & Technical Operationsno datano datano data
Kari Loeser
VP & Chief Compliance Officer3.1yrsno datano data
John Faurescu
VP, Associate General Counsel & Corporate Secretaryno datano datano data
Scott Jordan
Senior Vice President of Global Marketing & Commercial Strategy3.6yrsno datano data

3.7yrs

Average Tenure

60yo

Average Age

Experienced Management: CYTK's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Blum
CEO, President & Director17.9yrsUS$8.75m0.24%
$ 13.6m
James Spudich
Co-Founder & Member of Scientific Advisory Boardno dataUS$21.94kno data
B. Parshall
Independent Director11.8yrsUS$529.02k0.013%
$ 727.9k
James H. Sabry
Co-Founder & Chairman of Scientific Advisory Board16.7yrsUS$41.50kno data
Nancy Wysenski
Independent Director4.1yrsUS$519.02k0.015%
$ 843.6k
John Henderson
Independent Chairman15.8yrsUS$559.02k0.036%
$ 2.1m
John Lowe
Member of Scientific Advisory Boardno datano datano data
Thomas Pollard
Member of Scientific Advisory Boardno datano datano data
David Morgans
Member of Scientific Advisory Board8.4yrsUS$942.23kno data
Lawrence S. Goldstein
Member of Scientific Advisory Boardno datano datano data
John Solaro
Member of Scientific Advisory Boardno datano datano data
Muna Bhanji
Independent Director3.8yrsUS$509.02k0.010%
$ 583.6k

11.8yrs

Average Tenure

68yo

Average Age

Experienced Board: CYTK's board of directors are seasoned and experienced ( 11.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 07:39
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cytokinetics, Incorporated is covered by 36 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Jason ZemanskyBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.